Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24512547 | 0.96 | LMNA (0.39) | LMNAMAPTHSD17B10TP53TSHR | |
| SCHEMBL17449686 | 0.90 | NAMPT (0.42) | LMNAMAPT | |
| SCHEMBL23961901 | 0.89 | KDM4E (0.36) | LMNAMAPTTP53TSHRNOTUM | |
| SCHEMBL23961886 | 0.89 | TSHR (0.38) | LMNAMAPTHSD17B10TSHRNOTUM | |
| SCHEMBL24928129 | 0.88 | MTNR1A (0.42) | LMNAMAPTHSD17B10TP53TSHR | |
| SCHEMBL24775042 | 0.87 | SMN1; SMN2 (0.40) | LMNAMAPTTSHRNOTUM | |
| SCHEMBL27005846 | 0.87 | KDM4E (0.38) | LMNAMAPTTSHRNOTUM | |
| SCHEMBL18880167 | 0.87 | LMNA (0.41) | LMNAMAPTHSD17B10TP53TSHR | |
| SCHEMBL18737173 | 0.86 | LMNA (0.39) | LMNAMAPTHSD17B10TP53 | |
| SCHEMBL24928124 | 0.86 | NAMPT (0.45) | LMNAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-21 | — | — | US | disclosed |
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | SAPREME TECHNOLOGIES B.V. (NL) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293562-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | ASGR1, HCCS, HAVCR2 | LMNA 941/4885MAPT 1948/4885HSD17B10 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.